Platelet rich plasma (PRP) is an autologous solution comprised of a high concentration of platelets and WBC’s suspended in plasma. Platelets, or Thrombocytes, are a natural source of growth factors. Platelets circulate in the blood and are involved in hemostasis, leading to the formation of blood clots. White blood cells, or Leukocytes, are cells involved in defending the body against infections. WBC’s are the body’s first line of defense in fighting infection. When activated, these platelets release a large variety of known growth factors that accelerate the body’s natural healing process.
WHAT ARE AUTOLOGOUS PRP EYE DROPS
Autologous Platelet Rich Plasma (PRP) is concentrated platelets and white blood cells produced through centrifugation of the patient’s own blood. At the time of the procedure, a small volume of blood is drawn from the patient via venipuncture. The blood sample is then concentrated via centrifugation. Upon concentration, the platelets are removed and prepared for eye drops.
In our experience, we have found that patients who have been unable to obtain relief through other methods may have success with this treatment. The treatment is very safe and effective for the treatment of chronic and symptomatic Dry Eye Syndrome. Other indications for the use of Autologous PRP Eye Drops may include Dormant Ulcers and Ocular Surface Syndrome Post LASIK.
BENEFITS OF AUTOLOGOUS PRP EYE DROPS
- Accelerated and enhanced healing
- Reduced inflammation
- Symptomatic improvement of Dry Eye Syndrome
The known contraindications for Autologous PRP eye drops:
- Platelet Dysfunction Syndrome
- Critical Thrombocytopenia
- Ongoing Dry Eye Infection
Please notify your physician if you have any of the known contraindications listed above.
Costs: At this time, Autologous PRP Eye Drops are NOT covered by insurance companies. Therefore, it is an out-of-pocket expense to the patient.
PRP In The Literature
The clinical use of PRP has been studied in many medical specialties, including Orthopedics, Plastics, ENT, OB/GYN, Ophthalmology, Oral, and General surgery. For more information, we have referenced the following literature:
Alio J, Colecha J, et al. Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma. Ophthalmic Res 2007; 39: 124-129.
Alio J, Pastor S, et al. Treatment of Ocular Surface Syndrome after LASIK with Autologous Platelet-rich Plasma. Journal of Refractive Surgery 2007; 23: 617-619.
Alio J, Abad M, et al. Use of Autologous Platelet-Rich Plasma in the Treatment of Dormant Corneal Ulcers. Ophthalmology 2007; 114: 1286-1293.
Koffler B. Autologous Serum Therapy of the Ocular Surface with Novel Delivery by Platelet Concentrate Gel. The Ocular Surface 2006; 4(4): 188-195.
Marquez-de-Arecena R, Montero-de-Espinosa I, et al. Subconjunctival Application of Platelet Rich Plasma Concentrate in the Treatment of Ocular Burns: Preliminary Results. Arch Soc Esp Oftalmol 2007; 82: 475-482.